Genentech Drops The Other Shoe

We all knew it was just a matter of time until the “special committee” appointed to review the Roche officially rejected the buyout offer of $89/share.
The press release indicates a willingness to listen to offers that “recognizes the value of the company and reflects the significant benefits that would accrue” to an acquiring company.
Move along [...]

Roche on Spending Spree

First Roche offers to buy Genentech for ~$44B and in two consecutive days has inked two more deals.
Yesterday, in its second RNAi play in a year, Roche bought Mirus Bio for $125M. The acquisition should add value to the July 2007 preclinical discovery deal with RNAi leader Alnylam. Under the agreement, Mirus will [...]

Will Roche Kill Independent Genentech?

Roche has offered to buy the 45% stake of Genentech it doesn’t already own with a $89/share, $43.7B (8.8% premium) offer.
The initial Roche/Genentech deal brokered in the 90’s has been key to Roche’s success in the last few years. Upon first blush, this deal seems a natural fit and a no-brainer for Roche but [...]

ThromboGenics and BioInvent Ink Deal With Roche

Image via Wikipedia

BioInvent and ThromboGenics have entered into a license agreement with Roche for, TB-403, their novel mAb targeting Placental Growth Factor (PIGF) for the treatment of cancer. Under the terms of the agreement:
Roche will pay BioInvent and ThromboGenics an upfront payment of €50 million. In addition, BioInvent and ThromboGenics could potentially receive up to [...]

Genentech and Symphogen Team Up For $330M

Image via Wikipedia

I try not to be biased, but it’s not too often I discuss danish biotech companies on this blog.  Today is different. We are having a full international day here at Pharmababble.  First the Daiichi news and now this release of a collaboration from Symphogen and Genentech.  
The specifics of the alliance are [...]

Biopharm Closing Bell: 5/16/08

Top Movers

Gainers (% price change)
Last Trade
Change
Mkt Cap

Pharmacopeia, Inc.
PCOP
4.04
+0.86 (27.05%)
119.80M

Electro-Optical Sciences,
MELA
7.95
+0.93 (13.25%)
122.44M

Infinity Pharmaceuticals
INFI
8.02
+0.62 (8.38%)
158.37M

Cambrex Corporation
CBM
5.99
+0.42 (7.54%)
174.21M

Metropolitan Health
MDF
2.00
+0.14 (7.53%)
103.77M

Losers (% price change)
 

Tercica, Inc.
TRCA
3.82
-0.36 (-8.61%)
197.05M

Trubion Pharmaceuticals,
TRBN
6.61
-0.55 (-7.68%)
118.00M

Sucampo Pharmaceuticals,
SCMP
10.33
-0.83 (-7.44%)
431.11M

3SBio Inc. (ADR)
SSRX
10.06
-0.80 (-7.33%)
218.48M

Savient Pharmaceuticals,
SVNT
22.69
-1.46 (-6.05%)
1.23B

Most Actives (dollar volume)
 

Pfizer Inc.
PFE
20.03
-0.05 (-0.25%)
135.51B

Johnson & Johnson
JNJ
66.68
+0.00 (0.00%)
187.92B

Genentech, Inc.
DNA
70.19
+1.36 (1.98%)
73.76B

Merck & Co., Inc.
MRK
40.00
+0.00 (0.00%)
85.86B

Intuitive Surgical, Inc.
ISRG
299.75
+6.77 (2.31%)
11.60B